Knoll Pharma: PBT rises 29% in 1HFY02 - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Knoll Pharma: PBT rises 29% in 1HFY02

Jul 16, 2001

Knoll Pharmaceuticals, formerly Indian subsidiary of Knoll AG, has declared excellent performance for first half of FY02 in line with our expectation (Better days ahead). Apparently, net profit has dropped by 27% due to inclusion of an extraordinary income to the tune of Rs 161 m in the last year from sale of mutual fund units. The performance in second quarter is remarkable considering that there was a drop in operating profit in the first quarter on the back of cut in Ibuprofen prices by NPPA in January this year. Ibuprofen is a bulk drug which is used in pain management segment. As Knoll Pharma is a market leader in the Ibuprofen market, the price cut had a severe impact on the company's financials in the first quarter.

(Rs m)2QFY012QFY02% ChangeH1FY01H1FY02% Change
Sales 897 932 3.8% 1,628 1,745 7.2%
Other Income 30 96 220.0% 67 121 80.6%
Expenditure 763 768 0.6% 1,371 1,469 7.1%
Operating Profit (EBDIT) 134 164 22.4% 257 276 7.4%
Operating Profit Margin (%)14.9%17.6%17.9%15.8%15.8%0.2%
Interest 7 1 -92.9% 8 2 -81.3%
Depreciation 14 12 -17.1% 26 23 -13.1%
Profit before Tax 143 248 73.4% 290 373 28.6%
Extraordinary Income 161 - 161 - -100.0%
Tax 30 52 73.3% 58 85 46.6%
Profit after Tax/(Loss) 274 196 -28.5% 393 288 -26.7%
Net profit margin (%)12.6%21.0%14.3%16.5%
No. of Shares (eoy) (m) 16 16 1616
Diluted Earnings per share* 67.7 48.449.136.0
P/E (at current price) 4.4 6.26.18.3
(*- annualised)

The jump in operating margins in the second quarter was on the back of upward revision of four formulations of Insulin injection in March. Insulin Vial prices have increased by 22% - 25% since then. Insulin is the biggest revenue churner for Knoll where the company has a market share of close to 60%.

Abbot Labs had recently made an open offer at Rs 328 per share to the shareholders of Knoll Pharma covering 20% of the company's equity. This follows Abbot's acquisition of Lupharma UK Holding One Ltd. which in turn holds a 51% stake in Knoll Pharmaceuticals.The free float of the company post acquisition is very limited. At the current market price of Rs 299, the stock is trading at a P/e of 7x its FY02 expected earnings. There company's financials in the coming year may receive substaintial boost if insulin prices remain stable at current levels.

Equitymaster requests your view! Post a comment on "Knoll Pharma: PBT rises 29% in 1HFY02". Click here!

  

More Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY22); Net Profit Up 8.5% (Quarterly Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

For the quarter ended June 2021, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 8.5% YoY). Sales on the other hand came in at Rs 12 bn (up 14.4% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA 2020-21 Annual Report Analysis (Annual Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

Here's an analysis of the annual report of ABBOTT INDIA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of ABBOTT INDIA. Also includes updates on the valuation of ABBOTT INDIA.

ABBOTT INDIA Announces Quarterly Results (4QFY21); Net Profit Up 37.4% (Quarterly Result Update)

Jul 8, 2021 | Updated on Jul 8, 2021

For the quarter ended March 2021, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 37.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Dec 2, 2021 12:21 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - PROCTER & GAMBLE HEALTH COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS